Hansa Biopharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	222.27	171.32	134.09	154.53	33.88
Revenue Growth (YoY)	29.74%	27.76%	-13.22%	356.12%	455.56%
Cost of Revenue	83.56	83.55	63.14	38.48	15.43
Gross Profit	138.71	87.76	70.95	116.05	18.45
Selling, General & Admin	356.55	344.27	450.49	337.86	327.27
Research & Development	304.74	375.72	411.33	346.24	230.76
Other Operating Expenses	-1.87	-0.59	0.29	8.06	-
Operating Expenses	659.42	719.4	862.11	692.17	558.03
Operating Income	-520.71	-631.64	-791.16	-576.12	-539.58
Interest Expense	-117.63	-134.08	-105.52	-43.67	-0.69
Interest & Investment Income	170.8	20.83	28.06	8.83	0.07
Currency Exchange Gain (Loss)	-	-71.98	37.81	5.95	-7.4
Other Non Operating Income (Expenses)	-	12.65	-	-4.97	-0.53
EBT Excluding Unusual Items	-467.54	-804.21	-830.81	-609.98	-548.13
Merger & Restructuring Charges	-59.45	-	-	-	-
Pretax Income	-526.98	-804.21	-830.81	-609.98	-548.13
Income Tax Expense	2.27	3.03	0.91	1.16	0.15
Net Income	-529.25	-807.24	-831.72	-611.13	-548.28
Net Income to Common	-529.25	-807.24	-831.72	-611.13	-548.28
Shares Outstanding (Basic)	81	63	53	45	44
Shares Outstanding (Diluted)	81	63	53	45	44
Shares Change (YoY)	29.23%	19.59%	16.95%	1.01%	5.45%
EPS (Basic)	-6.52	-12.85	-15.83	-13.60	-12.33
EPS (Diluted)	-6.52	-12.85	-15.83	-13.60	-12.33
Free Cash Flow	-549.17	-675	-755.94	-506.06	-483.57
Free Cash Flow Per Share	-6.76	-10.74	-14.39	-11.27	-10.87
Gross Margin	62.41%	51.23%	52.91%	75.10%	54.47%
Operating Margin	-234.27%	-368.70%	-590.00%	-372.83%	-1592.71%
Profit Margin	-238.12%	-471.20%	-620.25%	-395.49%	-1618.40%
Free Cash Flow Margin	-247.08%	-394.01%	-563.74%	-327.50%	-1427.38%
EBITDA	-518.16	-629.08	-788.33	-573.71	-538.06
EBITDA Margin	-233.13%	-	-	-	-
D&A For EBITDA	2.55	2.55	2.83	2.41	1.52
EBIT	-520.71	-631.64	-791.16	-576.12	-539.58
EBIT Margin	-234.27%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.